New River To Co-Promote ADHD Drug With Shire
This article was originally published in The Pink Sheet Daily
Executive Summary
New River said it will exercise its right to promote with Shire the ADHD treatment NRP104, currently pending at FDA. New River's co-promotion activities will commence in six months or upon the commercial launch of the amphetamine product
You may also be interested in...
Shire’s New ADHD Drug Coming Into Focus
Connexyn (guanfacine extended release) could be approved in mid-2007 and would be the second non-stimulant in category.
Shire’s New ADHD Drug Coming Into Focus
Connexyn (guanfacine extended release) could be approved in mid-2007 and would be the second non-stimulant in category.
Shire, New River Submit NDA For Amphetamine Prodrug NRP104
Firms say lower abuse liability is potential advantage over other stimulant attention deficit/hyperactivity disorder treatments.